Urologia · 2026
Multicenter study on the effectiveness of entomological extract-based therapy in men with lower urinary symptoms associated with benign prostatic hyperplasia and chronic prostatitis.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kasyan George, Khodyreva Lyubov, Grigoryan Bagrat, Dyakov Vladimir
Аннотация
INTRODUCTION AND OBJECTIVES: Benign prostatic hyperplasia (BPH) and chronic prostatitis (CP) are common causes of lower urinary tract symptoms (LUTS) in men. This multicenter study evaluated the efficacy of an entomological extract-based treatment (EEBT) as monotherapy and in combination with standard drugs.
MATERIALS AND METHODS: A total of 6375 men with LUTS (IPSS ⩾ 10, Qmax 5-15 mL/s) were included; 1498 had BPH, 3060 had CP, and 1817 had both. Group I received EEBT monotherapy, while Group II underwent combination therapy with α1-adrenergic blockers, NSAIDs, antibiotics, and other agents. Outcomes were assessed after 30 days using NIH-CPSI, IPSS, IIEF-5, QoL, Qmax, prostate volume, and residual urine.
RESULTS: Both regimens significantly improved LUTS. In BPH patients, monotherapy reduced prostate and residual urine volumes and improved IIEF-5, whereas combination therapy provided greater symptom relief. In CP patients, both regimens improved NIH-CPSI, IPSS, and urinary flow, with monotherapy showing superior QoL benefits. In men with BPH + CP, monotherapy favored erectile function, while combination therapy improved IPSS. All subgroups demonstrated significant gains in Qmax. Treatment was well tolerated; only mild Clavien-Dindo grade I and II adverse events were reported, with no serious complications.
CONCLUSION: EEBT is effective as both monotherapy and in combination therapy for LUTS associated with BPH and CP, supporting its role in personalized treatment strategies.
MATERIALS AND METHODS: A total of 6375 men with LUTS (IPSS ⩾ 10, Qmax 5-15 mL/s) were included; 1498 had BPH, 3060 had CP, and 1817 had both. Group I received EEBT monotherapy, while Group II underwent combination therapy with α1-adrenergic blockers, NSAIDs, antibiotics, and other agents. Outcomes were assessed after 30 days using NIH-CPSI, IPSS, IIEF-5, QoL, Qmax, prostate volume, and residual urine.
RESULTS: Both regimens significantly improved LUTS. In BPH patients, monotherapy reduced prostate and residual urine volumes and improved IIEF-5, whereas combination therapy provided greater symptom relief. In CP patients, both regimens improved NIH-CPSI, IPSS, and urinary flow, with monotherapy showing superior QoL benefits. In men with BPH + CP, monotherapy favored erectile function, while combination therapy improved IPSS. All subgroups demonstrated significant gains in Qmax. Treatment was well tolerated; only mild Clavien-Dindo grade I and II adverse events were reported, with no serious complications.
CONCLUSION: EEBT is effective as both monotherapy and in combination therapy for LUTS associated with BPH and CP, supporting its role in personalized treatment strategies.